Skip to main content
Loading

Bexion Pharmaceuticals

February 26, 2024
Oncology
Bexion Pharmaceuticals
Bexion Pharmaceuticals is a mid-clinical stage biotechnology company developing biologics for the treatment of solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN). Our lead asset BXQ-350 modulates sphingolipid metabolism, increasing the ratio of certain ceramides to S1P in dysregulated cells, allowing for programmed cell death, reduced proliferation, and immune stimulation. The product has also been shown to potentially prevent and treat CIPN.
Testimonials

Conference Sponsors


 

Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.

SIGN UP